<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713556</url>
  </required_header>
  <id_info>
    <org_study_id>09 106 01</org_study_id>
    <nct_id>NCT01713556</nct_id>
  </id_info>
  <brief_title>Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial</brief_title>
  <acronym>REDUCTRAUMA2</acronym>
  <official_title>Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether propranolol, when given during a re-evocation of&#xD;
      a traumatic memory, is capable of reducing subsequent PTSD symptoms associated with that&#xD;
      memory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-traumatic stress disorder (PTSD) develops following an exposure to a life threatening&#xD;
      event. One of the characteristic features of PTSD is the recurrence of intrusive memories of&#xD;
      an experienced trauma. The persistence of disturbing traumatic memories in PTSD is often&#xD;
      explained in terms of a trauma-induced enhancement of memory encoding. Several studies&#xD;
      indicate that an increased noradrenergic activity during trauma enhances the encoding of&#xD;
      memory. Elevated levels of norepinephrine in the cerebrospinal fluid of individuals with PTSD&#xD;
      and the correlation of this elevation with the severity of PTSD symptoms suggest that&#xD;
      increased noradrenergic activity is also involved in the maintenance of PTSD symptoms.&#xD;
      Reactivation of memory by retrieval also renders the memory labile and susceptible to&#xD;
      treatments. This latter process is referred to as memory reconsolidation. Consolidation and&#xD;
      reconsolidation both occur within a distinct time window following new learning (in&#xD;
      consolidation) and/or retrieval (in reconsolidation). Even well-consolidated old fear&#xD;
      memories undergo reconsolidation and may be disrupted by means of pharmacological&#xD;
      manipulation. Propranolol may be effective in treating PTSD long after symptoms have been&#xD;
      consolidated. Propranolol given after reactivation of the memory of a past traumatic event&#xD;
      reduces physiologic responding during subsequent mental imagery of the event.&#xD;
&#xD;
      HYPOTHESE: Subjects with chronic PTSD who receive propranolol before trauma evocation will&#xD;
      subsequently show decreased PTSD symptoms, compared to subjects who receive a placebo.&#xD;
&#xD;
      METHOD: 56 participants with chronic PTSD will be recruited for participation. On Week 1, the&#xD;
      subjects will complete a standardized measure of PTSD symptoms. Next, 90 minutes after the&#xD;
      administration of the study medication (either propranolol or placebo), participants will&#xD;
      undergo a script preparation procedure, during which they will disclose details of their&#xD;
      traumatic event. Scripts portraying this event will be prepared for subsequent replay.&#xD;
&#xD;
      On Week 2, after the administration of the study medication (either propranolol or placebo),&#xD;
      participants will be asked (reading the script) to engaged in a script-driven mental imagery&#xD;
      of the traumatic event. Following this procedure, PTSD symptoms will be assessed.&#xD;
&#xD;
      The same procedure will be repeated on Weeks 3, 4, 5 and 6. On Weeks 7 and 18, the&#xD;
      standardized measure of PTSD symptoms will be repeated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2012</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTCD CheckList (PCL) total score.</measure>
    <time_frame>difference between week 1 (before administration of the study medication) and week 7 (one week after the last intake of study medication)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Propranolol + reactivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>they have a script-driven mental imagery of the traumatic event white drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + reactivation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They have a script-driven mental imagery of the traumatic event with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <arm_group_label>Propranolol + reactivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Trauma reactivation</intervention_name>
    <description>Trauma reactivation: script-driven mental imagery of the traumatic event</description>
    <arm_group_label>Placebo + reactivation</arm_group_label>
    <arm_group_label>Propranolol + reactivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo + reactivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic PTSD&#xD;
&#xD;
          -  PTSD CheckList total score &gt;44&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic blood pressure &lt; 100 mmHg&#xD;
&#xD;
          -  Contraindication to Propranolol&#xD;
&#xD;
          -  Previous adverse reaction to a β-blocker&#xD;
&#xD;
          -  Use of another β-blocker&#xD;
&#xD;
          -  Use of medication that could involve potentially dangerous interactions with&#xD;
             propranolol&#xD;
&#xD;
          -  Psychotherapy or treatment with any pharmacologic PTSD medication within the 2 weeks&#xD;
             prior to inclusion (6 weeks for fluoxetine)&#xD;
&#xD;
          -  Female with reproductive potential without reliable means of contraception&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe BIRMES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 22, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD, Propranolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

